House
Create account
Drug reference directory
Drug reference

lisocabtagene maraleucel

Antineoplastic agent (CD19 CAR-T cell therapy)

Antineoplastic agent (CD19 CAR-T cell therapy)
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
  • EtanerceptSevereDatabaseDDInter
  • FingolimodSevereDatabaseDDInter
  • GolimumabSevereDatabaseDDInter
  • InfliximabSevereDatabaseDDInter

Mechanism

Not yet extracted

Drug interactions

Etanercept
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Fingolimod
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Golimumab
Severe
Database

Clinical effect not specified

Source: DDInter

Infliximab
Severe
Database

Clinical effect not specified

Source: DDInter

Leflunomide
Severe
Database

Clinical effect not specified

Source: DDInter

Measles Virus Vaccine Live Attenuated
Severe
Database

Clinical effect not specified

Source: DDInter

Natalizumab
Severe
Database

Clinical effect not specified

Source: DDInter

Ozanimod
Severe
Database

Clinical effect not specified

Source: DDInter

Rotavirus Vaccine
Severe
Database

Clinical effect not specified

Source: DDInter

Siponimod
Severe
Database

Clinical effect not specified

Source: DDInter

Talimogene Laherparepvec
Severe
Database

Clinical effect not specified

Source: DDInter

Teriflunomide
Severe
Database

Clinical effect not specified

Source: DDInter

Other Unclassified drugs

5-9-tetrahydrocannabinol
0 brands
6-mercaptopurine
0 brands
acetylsalicylic acid
0 brands
acotiamide
0 brands
acoziborole
0 brands
activated charcoal
0 brands
adrenaline
0 brands
adrenochrome monosemicarbazone
0 brands

Ask House about lisocabtagene maraleucel

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Textbook-sourced·Sources: Harrison 22e·Updated: 2026-05-10